Neuropsychiatric Effects in Patients With Invasive Prolactinomas Treated With Cabergoline

Area of Science:

• Neuroendocrinology
• Clinical Neurology
• Psychiatry

Background:

• Invasive prolactinomas, a rare subtype, can cause significant neurological and psychiatric issues due to mass effect.
• Neuropsychiatric symptoms associated with invasive prolactinomas are often overlooked in initial assessments.
• Cabergoline is the standard treatment, but its impact on these specific symptoms is not well understood.

Purpose of the Study:

• To investigate the prevalence of neuropsychiatric comorbidities in Mexican patients with invasive prolactinomas.
• To evaluate the effect of cabergoline treatment on these neuropsychiatric symptoms.

Main Methods:

• A retrospective analytic study design was employed.
• Data were collected from clinical records of patients at baseline and six-month follow-ups.
• Standardized clinical scales were used to assess neuropsychiatric comorbidities.

Main Results:

• Out of 10 patients with invasive prolactinomas, none had prior psychiatric diagnoses, but 70% presented with depression or anxiety initially.
• During follow-up, two patients developed new neuropsychiatric symptoms.
• A significant reduction in tumor size was observed with cabergoline, but no significant improvement in neuropsychiatric symptom scores was noted.

Conclusions:

• Invasive prolactinomas are associated with a high incidence of neuropsychiatric symptoms.
• Cabergoline's effect on these symptoms may be complex, potentially involving dopaminergic pathways.
• This pilot study suggests further research is needed to understand cabergoline's role in managing neuropsychiatric aspects of invasive prolactinomas.